EGFR and neoplasm: Because EGFR-mutated tumours often remain sensitive to ErbB targeting agents beyond progression, thus allowing re-introduction of these agents in later lines of therapy, it is important to test whether chemotherapy impacts on the sensitivity to these drugs.